His main research concerns Plasminogen activator, Molecular biology, Plasminogen activator inhibitor-1, Biochemistry and Vitronectin. His Plasminogen activator research incorporates themes from Serpin, Neuroserpin, Ischemia and Tissue plasminogen activator. His Tissue plasminogen activator study incorporates themes from Familial encephalopathy with neuroserpin inclusion bodies and Cell biology.
His biological study spans a wide range of topics, including Endothelial stem cell, Plasminogen Inactivators, Integrin, Fibrinolysis and Endothelium. His study in Plasminogen activator inhibitor-1 is interdisciplinary in nature, drawing from both Cell adhesion, Reactive center and Binding site. His work carried out in the field of Vitronectin brings together such families of science as Cell migration, Angiogenesis and Plasmin.
Plasminogen activator, Plasminogen activator inhibitor-1, Biochemistry, Vitronectin and Molecular biology are his primary areas of study. His Plasminogen activator research integrates issues from Fibrinolysis, Tissue plasminogen activator and Serpin. His Plasminogen activator inhibitor-1 research is multidisciplinary, relying on both Cancer research, Plasmin, Binding site, Reactive center and In vivo.
His Mutant, Protease, Proteases and Serine study in the realm of Biochemistry connects with subjects such as Covalent bond. His Vitronectin research is multidisciplinary, incorporating perspectives in Angiogenesis, Cell adhesion and Small molecule. His Molecular biology research includes themes of Plasminogen Inactivators, Peptide sequence and Recombinant DNA.
Daniel A. Lawrence mainly focuses on Plasminogen activator, Plasminogen activator inhibitor-1, Tissue plasminogen activator, Pharmacology and Internal medicine. His research in Plasminogen activator intersects with topics in Ex vivo, Serpin, Fibrin, Fibrinolysis and Thrombosis. His Serpin study is concerned with Biochemistry in general.
His Plasminogen activator inhibitor-1 study combines topics in areas such as Biophysics, Vitronectin, Plasmin and Urokinase. His studies deal with areas such as Inflammation, Neuroserpin, Stroke, Genetically modified mouse and Cell type as well as Tissue plasminogen activator. His Internal medicine study combines topics from a wide range of disciplines, such as Pathology, Endocrinology, Flow cytometry and Cardiology.
His primary scientific interests are in Plasminogen activator, Blood–brain barrier, Tissue plasminogen activator, Pharmacology and Immunology. His research on Plasminogen activator focuses in particular on Plasminogen activator inhibitor-1. His Plasminogen activator inhibitor-1 study integrates concerns from other disciplines, such as Proteases, Serpin, Biochemistry, Venous thrombosis and Vitronectin.
Daniel A. Lawrence has researched Blood–brain barrier in several fields, including Neuroprotection and Pathology. His Pathology study deals with Internal medicine intersecting with Ex vivo and Endocrinology. His research in Tissue plasminogen activator focuses on subjects like Stroke, which are connected to Transplantation, LRP1, Integrin alpha M and Randomized controlled trial.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin.
Steingrimur Stefansson;Daniel A. Lawrence.
Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein
Manuel Yepes;Maria Sandkvist;Elizabeth G. Moore;Thomas H. Bugge.
Journal of Clinical Investigation (2003)
Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells.
J A van Mourik;D A Lawrence;D J Loskutoff.
Journal of Biological Chemistry (1984)
Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor.
Tor Ny;M Sawdey;D Lawrence;J L Millan.
Proceedings of the National Academy of Sciences of the United States of America (1986)
Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells.
D J Loskutoff;J A van Mourik;L A Erickson;D Lawrence.
Proceedings of the National Academy of Sciences of the United States of America (1983)
Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke
Enming J Su;Linda Fredriksson;Melissa Geyer;Erika Folestad.
Nature Medicine (2008)
Familial dementia caused by polymerization of mutant neuroserpin
Richard L. Davis;Antony E. Shrimpton;Peter D. Holohan;Charles Bradshaw.
Platelet-derived Growth Factor (PDGF)-induced Tyrosine Phosphorylation of the Low Density Lipoprotein Receptor-related Protein (LRP) EVIDENCE FOR INTEGRATED CO-RECEPTOR FUNCTION BETWEEN LRP AND THE PDGF
Elena Loukinova;Sripriya Ranganathan;Sergey Kuznetsov;Natalia Gorlatova.
Journal of Biological Chemistry (2002)
Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis.
Grainne A. McMahon;Eric Petitclerc;Steingrimur Stefansson;Elizabeth Smith.
Journal of Biological Chemistry (2001)
Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis.
Manuel Yepes;Manuel Yepes;Manuel Yepes;Maria Sandkvist;Maria Sandkvist;Maria Sandkvist;Mike K.K. Wong;Timothy A. Coleman;Timothy A. Coleman;Timothy A. Coleman.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: